ERRFI1 Underexpression

CI-VAR-00004420Explore in graph →CIViC 2386

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
ERRFI1 Underexpression	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Predictive	D	Supports Sensitivity Response	3	submitted	EID6379 EGFR activity was markedly decreased during the evolution of resistance to the EGFR tyrosine kinase inhibitor (TKI) erlotinib, with a concomitant increase of ERRFI1(Mig6), a negative regulator of EGFR… (full text at CIViC) PMID 23935914 · Chang et al., 2013 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.